135 related articles for article (PubMed ID: 19480415)
1. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
Linder KE; Metcalfe E; Arunachalam T; Chen J; Eaton SM; Feng W; Fan H; Raju N; Cagnolini A; Lantry LE; Nunn AD; Swenson RE
Bioconjug Chem; 2009 Jun; 20(6):1171-8. PubMed ID: 19480415
[TBL] [Abstract][Full Text] [Related]
2. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
[TBL] [Abstract][Full Text] [Related]
3. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.
Cagnolini A; Chen J; Ramos K; Skedzielewski TM; Lantry LE; Nunn AD; Swenson RE; Linder KE
Appl Radiat Isot; 2010 Dec; 68(12):2285-92. PubMed ID: 20638858
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
5. Isolation of a 177Hf complex formed by beta-decay of a 177Lu-labeled radiotherapeutic compound and NMR structural elucidation of the ligand and its Lu and Hf complexes.
Cagnolini A; D'Amelio N; Metcalfe E; Nguyen HD; Aime S; Swenson RE; Linder KE
Inorg Chem; 2009 Apr; 48(7):3114-24. PubMed ID: 19243162
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
[TBL] [Abstract][Full Text] [Related]
7. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR
J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357
[TBL] [Abstract][Full Text] [Related]
8. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.
Waser B; Eltschinger V; Linder K; Nunn A; Reubi JC
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):95-100. PubMed ID: 16909223
[TBL] [Abstract][Full Text] [Related]
9. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
[TBL] [Abstract][Full Text] [Related]
10. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
[TBL] [Abstract][Full Text] [Related]
11. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
[TBL] [Abstract][Full Text] [Related]
12. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.
Thomas R; Chen J; Roudier MM; Vessella RL; Lantry LE; Nunn AD
Clin Exp Metastasis; 2009; 26(2):105-19. PubMed ID: 18975117
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
15. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
16. Structural assessment and biological evaluation of two N3S bombesin derivatives.
Gourni E; Bouziotis P; Benaki D; Loudos G; Xanthopoulos S; Paravatou-Petsotas M; Mavri-Vavagianni M; Pelecanou M; Archimandritis SC; Varvarigou AD
J Med Chem; 2009 Jul; 52(14):4234-46. PubMed ID: 19522464
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.
Ho CL; Liu IH; Wu YH; Chen LC; Chen CL; Lee WC; Chuang CH; Lee TW; Lin WJ; Shen LH; Chang CH
J Biomed Biotechnol; 2011; 2011():101497. PubMed ID: 21660132
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells.
Ghosh A; Raju N; Tweedle M; Kumar K
Cancer Biother Radiopharm; 2017 Feb; 32(1):24-32. PubMed ID: 28186846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]